PharmaCyte logs $8.36M loss on volatile investment marks; advances FDA work, raises cash

PharmaCyte Biotech, Inc. (OTCBB: PMCB)

Quick read: PharmaCyte is a small-cap biotech focused on its Cell‑in‑a‑Box® CypCaps™ program for pancreatic cancer. The company reduced operating spend, made progress on FDA requests, and completed financing steps after quarter‑end - but booked a large quarter loss driven by mark‑to‑market swings in strategic investments and warrants. Internal control weaknesses and a paused spending posture on some programs remain risks.

Key facts & figures (as reported July 31, 2025)
* Cash and cash equivalents: $13,178,305 (April 30, 2025: $15,172,163)
* Total current assets: $19,106,338 (Apr 30: $22,375,238)
* Total assets: $45,110,453 (Apr 30: $55,168,353)
* Total liabilities: $1,518,865 (Apr 30: $3,277,284)
* Total stockholders' equity: $43,591,588 (Apr 30: $51,891,069)
* Accumulated deficit: $(93,329,056) (Apr 30: $(84,968,960))
* Treasury stock: 14,876,316 shares at cost $44,607,916
* Common shares outstanding: 6,795,779 (weighted avg shares for EPS: 6,795,779)
* Warrants outstanding: 19,227,097 (weighted average exercise price $4.52)

Income statement - headline numbers (three months ended July 31, 2025)
* Revenue: $-
* Research & development: $95,157
* General & administrative: $753,148
* Total operating expenses: $848,305 → Loss from operations: $(848,305)
* Other income (loss), net: $(7,511,791) (driven by fair value changes)
* Net loss: $(8,360,096) (three months ended July 31, 2024: net income $23,421,355)
* Basic & diluted loss per share: $(1.23) (prior year: $1.90)

Major fair‑value / investment items that moved the quarter
* Change in fair value - convertible note receivable (Femasys): +$912,000
* Change in fair value - Femasys warrant asset: $(1,215,000)
* Change in fair value - investment (TNF): $(2,839,000)
* Change in fair value - TNF warrants: $(4,832,000)
* Unrealized loss on marketable securities: $(104,463)
* Net effect: large negative other income (loss) of $(7,511,791)

What's going on inside the company - operational & corporate highlights
* FDA clinical‑hold work: Company reports substantial progress - completed stability studies, sequencing and genetic stability work, biocompatibility studies (8 of 10 completed), and other CMC and device‑compatibility work. Management is in active dialogue with the FDA and SG Austria to lift the IND hold.
* Board/strategy: Reconstituted Board and Business/Scientific Committees are reviewing programs and the relationship with SG Austria; spending on development programs has been curtailed pending committee recommendations.
* Financing / transactions (post‑quarter): August 2025 private placement - Series C preferred + warrants, gross proceeds $7,000,000; September 2025 agreement to purchase TNF Series H preferred + warrants for $3,000,000 (subject to approvals). Company expects approximately $15.7M cash as of filing and says that will cover at least 12 months from the 10‑Q date.
* Settlements & warrants: Settlement with H.C. Wainwright required $1.55M payment and issuance of settlement warrants; new warrants issued and recorded as liabilities (liability classification for many warrants).

Positive aspects of the income statement & position
* Cash balance is meaningful for this stage: $13.18M at quarter‑end and management indicates ~ $15.7M after subsequent financings - provides runway for short term operations.
* Operating costs low: R&D of $95k and total operating expenses under $850k for the quarter - company has curtailed spending.
* Some mark‑to‑market gains: Femasys convertible note fair value increased by $912k in the quarter (partly offset elsewhere).
* Post‑period financing adds capital ($7M Series C) and strategic TNF transaction ($3M) to fund near‑term needs.

Negative aspects of the income statement & position
* Large net loss: $(8,360,096) for the quarter; EPS $(1.23). Loss driven mainly by volatile fair‑value losses on TNF and warrant positions rather than core operating costs.
* Big fair‑value volatility: $(2.839M) on TNF preferred + $(4.832M) on TNF warrants + $(1.215M) on Femasys warrants - these swings can materially distort GAAP results quarter‑to‑quarter.
* Declining assets / cash burn: Total assets fell from $55.17M to $45.11M; cash declined ~$2.0M in the quarter (cash used in operating activities $(1,993,981)).
* Accumulated deficit widened to $(93.33M) and treasury stock remains large ($44.6M cost), limiting equity flexibility.
* Governance & controls: Management disclosed material weaknesses in internal control (insufficient segregation of duties; insufficient management review) - a governance & disclosure risk.
* Clinical & dependency risk: IND still on clinical hold; key know‑how and manufacturing depend on SG Austria and the Board is reassessing that relationship - potential for program delays or termination.

Takeaway - short, direct
PharmaCyte (OTCBB: PMCB) is conserving cash and advancing the technical/regulatory work needed to address the FDA clinical hold while leaning on equity and related‑party investments (TNF, Femasys) that produced large GAAP swings this quarter. The company has runway from recent financings but remains exposed to: (1) continued fair‑value volatility of its investment holdings; (2) the outcome of FDA interactions and its relationship with SG Austria; and (3) material internal control weaknesses. For investors the story is high‑risk/high‑execution: technical progress on IND items is encouraging, but GAAP earnings and balance‑sheet volatility are significant and governance/operational execution will matter.